Regeneron Pharmaceuticals has announced a $3 billion manufacturing agreement with FUJIFILM Diosynth Biotechnologies in North Carolina, nearly doubling its U.S. large-scale manufacturing capacity for biologic medicines.
DelveInsight's latest report reveals a robust pipeline with over 195 companies developing 200+ therapies for colorectal cancer, highlighting significant innovation in targeted treatments and immunotherapies.
Merck KGaA confirms advanced acquisition discussions with SpringWorks Therapeutics, though critical conditions remain unmet and no binding agreement has been reached.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.